OGEN
$0.78
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States.
Intraday
Recent News
Oragenics previews targeted milestones for 2026
Oragenics (OGEN) previewed its targeted milestones for 2026. Oragenics is advancing its lead candidate ONP-002, a novel intranasal neurosteroid, through clinical studies as the potential first and only pharmacological treatment for concussion and mild traumatic brain injury. Oragenics’ CEO Janet Huffman commented, “Through successful operational, regulatory and financial execution over the past year, we achieved key strategic milestones that secured the clinical infrastructure required to enter
Oragenics partners with Duck Flats Pharma to support FDA IND trial design
Oragenics (OGEN) announced it has engaged Duck Flats Pharma as its U.S. Investigational New Drug, IND, readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design as the Company advances its novel intranasal concussion therapy toward U.S.-based development. The engagement is intended to align the Company’s upcoming Phase 2a clinical trial in Australia with its U.S regulatory strategy. “We highly value our collaboration with DUCK FLATS Pharma as we advan
Oragenics: Q3 Earnings Snapshot
SARASOTA, Fla. AP) — Oragenics Inc. OGEN) on Friday reported a loss of $3.1 million in its third quarter.
Oragenics partners Receptor.AI for brain health candidate portfolio
The partnership will harness AI modelling techniques to determine the ideal receptor binding profiles for new compounds.
Oragenics: Q2 Earnings Snapshot
SARASOTA, Fla. AP) — Oragenics Inc. OGEN) on Friday reported a loss of $2.3 million in its second quarter.